Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
CA 2468888 C · Owner: Salmi, Marko · Inventors: Irjala, Heikki; Jalkanen, Sirpa; Salmi, Marko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor- 1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 8, 2003 and granted March 12, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 8, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 8, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.